What Researchers Did
Researchers randomly assigned 68 herpes zoster patients to either a control group receiving drug therapy or a hyperbaric oxygen (HBO2) group receiving both drugs and HBO2.
What They Found
The HBO2 group showed a significantly higher therapeutic efficacy of 97.22% compared to 81.25% in the control group (p < 0.05). Patients receiving HBO2 also experienced significantly lower rates of post-herpetic neuralgia, faster scar formation, and reduced pain and depression scores (p < 0.05).
What This Means for Canadian Patients
Canadian patients with herpes zoster might experience enhanced healing, reduced pain, and a lower risk of developing post-herpetic neuralgia if hyperbaric oxygen therapy is added to their treatment. This could also potentially improve their mood and overall recovery from the condition.
Canadian Relevance
This study does not have a direct Canadian connection.
Study Limitations
The relatively small sample size of 68 patients may limit the generalizability of these findings.